Abstract
Background
Large bone defects remaining after curettage of benign bone tumors should be filled with a substitute to restore mechanical strength. In 2000, we developed a fully interconnected porous calcium hydroxyapatite ceramic (IPCHA, NEOBONE) and have utilized it as a bone substitute. IP-CHA has a finely organized, three-dimensional interconnecting pore structure. The large interconnecting channels (average diameter 40 μm) permit easy penetration of tissue into the deep pores, so IP-CHA can itself induce local bone repair processes. The purpose of this study was to evaluate the clinical outcomes with the use of IP-CHA as bone substitute after curettage of benign bone tumors.
Methods
We reviewed the results of 71 patients with benign bone tumors sequentially treated by curettage followed by implantation of IP-CHA between 2000 and 2006. There were 29 women and 42 men, with a mean age of 28 years. Assessment was based on radiography at each time point during the follow-up. Radiographic findings were classified into five stages: stage 0, no change; stage 1, slight bone formation; stage 2, moderate bone formation; stage 3, consolidation; stage 4, absorption.
Results
In 70 of 74 operated lesions, radiographs showed that implanted IP-CHA proceeded to stage 2 or more within an average of 8 months after the surgery. In addition, 17 lesions proceeded to stage 4 within 35 months after surgery, on average. However, there were 10 local recurrences, which is similar to the recurrence rate for such tumors treated with or without implantation of CHAs and reflects the biological nature of each tumor.
Conclusions
In this study, we utilized IP-CHA as a bone substitute after curettage of benign bone tumors and demonstrated its usefulness in the clinical situation. IP-CHA comparatively exhibited excellent bone formation at an early stage although the problem of recurrence of the tumor remained. We conclude that IP-CHA is a useful bone substitute for the treatment of benign bone tumors.
Similar content being viewed by others
References
Arrington ED, Smith WJ, Chambers HG, Bucknell AL, Davino NA. Complications of iliac crest bone graft harvesting. Clin Orthop 1996;329:300–309.
Nishikawa M, Ohgushi H. Calcium phosphate ceramics in Japan. In: Yaszemski MJ, Trantolo DJ, Lewandrowski KU, Hasirci V, Altobelli DE, Wise DL, editors. Biomaterials in orthopedics. New York: Marcel Dekker; 2004. p. 425–436.
Holmes RE, Bucholz RW, Mooney V. Porous hydroxyapatite as a bone graft substitute in diaphyseal defects: a histometric study. J Orthop Res 1987;5:114–121.
Matsumine A, Myoui A, Kusuzaki K, Araki N, Seto M, Yoshikawa H, et al. Calcium hydroxyapatite ceramic implants in bone tumor surgery: a long-term follow-up study. J Bone Joint Surg Br 2004; 86:719–725.
Uchida A, Araki N, Shinto Y, Yoshikawa H, Kurisaki E, Ono K. The use of calcium hydroxyapatite ceramic in bone tumour surgery. J Bone Joint Surg Br 1990;72:298–302.
Ayers RA, Simske SJ, Nunes CR, Wolford LM. Long-term bone ingrowth and residual micro hardness of porous block hydroxyapatite implants in humans. J Oral Maxillofac Surg 1998;56: 1297–1301.
Tamai N, Myoui A, Tomita T, Nakase T, Tanaka J, Och, T, et al. Novel hydroxyapatite ceramics with an interconnective porous structure exhibit superior osteoconduction in vivo. J Biomed Mater Res 2002;59A:110–117.
Arbeitsgemeinschaft Knochentumoren, Becker WT, Dohle J, Bernd L, Braun A, Cserhati M, Enderle A, et al. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am 2008;90:1060–1067.
Ogose A, Hotta T, Kawashima H, Kondo N, Gu W, Kamura T, et al. Comparison of hydroxyapatite and beta tricalcium phosphate as bone substitutes after excision of bone tumors. J Biomed Mater Res B Appl Biomater 2005;72:94–101.
Hirata M, Murata H, Takeshita H, Sakabe T, Tsuji Y, Kubo T. Use of purified beta-tricalcium phosphate for filling defects after curettage of benign bone tumours. Int Orthop 2006;30:510–513.
Iwai T, Harada Y, Imura K, Iwabuchi S, Murai J, Hiramatsu K, et al. Low-intensity pulsed ultrasound increases bone ingrowth into porous hydroxyapatite ceramic. J Bone Miner Metab 2007;25: 392–399.
Martin RB, Chapman MW, Sharkey NA, Zissimos SL, Bay B, Shors EC. Bone ingrowth and mechanical properties of coralline hydroxyapatite 1year after implantation. Biomaterials 1993;14: 341–348.
Deie M, Ochi M, Adachi N, Nishimori M, Yokota K. Artificial bone grafting [calcium hydroxyapatite ceramic with an interconnected porous structure (IP-CHA)] and core decompression for spontaneous osteonecrosis of the femoral condyle in the knee. Knee Surg Sports Traumatol Arthrosc 2008;16:753–758.
Kuriyama K, Hashimoto J, Murase T, Fujii M, Nampei A, Hirao M, et al. Treatment of juxta-articular intraosseous cystic lesions in rheumatoid arthritis patients with interconnected porous calcium hydroxyapatite ceramic. Mod Rheumatol 2009;19:180–186.
Schindler OS, Cannon SR, Briggs TW, Blunn GW. Composite ceramic bone graft substitute in the treatment of locally aggressive benign bone tumours. J Orthop Surg (Hong Kong) 2008; 16:66–74.
Schindler OS, Cannon SR, Briggs TW, Blunn GW. Use of a novel bone graft substitute in peri-articular bone tumours of the knee. Knee 2007;14:458–464.
Irwin RB, Bernhard M, Biddinger A. Coralline hydroxyapatite as bone substitute in orthopedic oncology. Am J Orthop 2001;30: 544–550.
Yamamoto T, Onga T, Marui T, Mizuno K. Use of hydroxyapatite to fill cavities after excision of benign bone tumours: clinical results. J Bone Joint Surg Br 2000;82:1117–1120.
Mattori G. Map of bone formation rate values recorded throughout the skeleton of the dog. In: Jaworski ZFG, Zlosevych S, Cameron E, editors. Proceedings of the 1st workshop on bone morphometry. Ottawa: University of Ottawa Press; 1976. p. 202–207.
Dempster DW. Bone remodeling. In: Coe FL, Favus MJ, editors. Disorders of bone and mineral metabolism, Philadelphia: Lippincott Williams & Wilkins; 2002. p. 315–343.
Cho HS, Oh JH, Kim HS, Kang HG, Lee SH. Unicameral bone cysts: a comparison of injection of steroid and grafting with autologous bone marrow. J Bone Joint Surg Br 2007;89:222–226.
Suneja R, Grimer RJ, Belthur M, Jeys L, Carter SR, Tillman RM, et al. Chondroblastoma of bone: long-term results and functional outcome after intralesional curettage. J Bone Joint Surg Br 2005;87:974–978.
Zhen W, Yaotian H, Songjian L, Ge L, Qingliang W. Giant-cell tumour of bone: the long-term results of treatment by curettage and bone graft. J Bone Joint Surg Br 2004;86:212–216.
Author information
Authors and Affiliations
About this article
Cite this article
Tamai, N., Myoui, A., Kudawara, I. et al. Novel fully interconnected porous hydroxyapatite ceramic in surgical treatment of benign bone tumor. J Orthop Sci 15, 560–568 (2010). https://doi.org/10.1007/s00776-010-1479-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00776-010-1479-8